Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Financial Results

MEDIFAST Shares Jump 14% in 14 Days Since Financial Results

Medifast Q3 2026 Results: Revenue Hits $72.05 Million Amid Widening Net Loss

+14.83% in 14 days $11.87 when we broke this story → $13.63 peak on 9 Nov 2026

Medifast reported a contraction in its third-quarter financial performance, with revenue falling to $72.05 million and net losses deepening significantly compared to the prior year. The company is currently undergoing a structural transition characterized by increased operating expenses and non-cash restructuring charges.

Workout, man, training, sports. Stock photo illustrating Medifast's financial results story.
MEDIFAST INC · Photo: Gabin_Vallet / Pixabay
Results at a glance · $ Million
Metric Q3-26Q3-25
Revenue 72.0589.41
Gross Profit 50.0462.16
Pretax Income -17.84-2.66
Net Income -17.51-2.26
Diluted EPS -1.57-0.21
Net Income YoY
-674.5%

Key highlights

  • Revenue declined to $72.05 million from $89.41 million in the prior year period
  • Net loss widened to $17.51 million compared to a $2.26 million loss in Q3 2025
  • Net income growth fell by 674.5% year-over-year
  • Company recorded a $10.8 million non-cash restructuring charge in the first nine months of 2026
  • Management issued Q4 2026 revenue guidance between $55 million and $75 million

How the Period Went

Medifast’s third-quarter performance showed a notable contraction, with revenue falling to $72.05 million compared to $89.41 million in the same period last year. This revenue decline contributed to a widening bottom-line deficit, as the company reported a net loss of $17.51 million, a sharp increase from the $2.26 million loss recorded in Q3 2025. Diluted earnings per share plummeted to -$1.57 from -$0.21 year-over-year. The results reflect a challenging period where the decrease in sales volume directly impacted the firm's ability to maintain its previous year's earnings trajectory, resulting in a net income decline of 674.5%.

Margins and Profitability

Profitability metrics were pressured by a combination of lower sales and elevated operational costs during the quarter. Gross profit decreased to $50.04 million from $62.16 million in the prior year, though the company maintained a substantial gross margin. However, profitability was severely impacted by rising selling, general, and administrative expenses alongside a non-cash restructuring charge of $10.8 million incurred during the first nine months of the year. Pretax income fell to a loss of $17.84 million, down from a $2.66 million loss in Q3 2025. These exceptional items and structural costs have shifted the company's margin profile as it navigates internal reorganization.

Business Overview

Medifast operates within the personal services industry of the consumer cyclical sector, primarily offering weight management and health-focused products through its OPTAVIA brand. The company’s business model centers on a community-led approach, utilizing a network of independent coaches to market habit-based health transformation programs. Medifast’s product portfolio includes various portion-controlled meal replacements and snacks designed to support long-term wellness. The company serves a diverse consumer base in the United States, focusing on holistic health interventions rather than singular dietary supplements, although it faces increasing competition from clinical and pharmaceutical weight-loss alternatives that have recently disrupted the traditional wellness market.

Financial Context

The Q3 2026 results continue a sequential downward trend in revenue, following $76.4 million in Q2 and $76.0 million in Q1 2026, as noted in previous investor updates. Management has provided full-year 2026 revenue guidance in the range of $280 million to $300 million, with a projected GAAP loss per share between $1.80 and $2.05. Despite the current financial headwinds, Medifast’s stock showed a 21.62% increase over the last quarter, though it remains under pressure with a market capitalization of approximately $132.7 million. The company maintains no significant order backlog, as customer orders are typically fulfilled within 48 business hours, according to its previous annual filings.

MEDIFAST INC share price · last month
Line chart of MEDIFAST INC's share price over the last month, from $12.03 on 19 Oct → $12.54 on 16 Nov; our story on 26 Oct at $11.87.

Up 5.6% since our story on 26 Oct: $11.87 when we broke it → $12.54 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$12.03
20 Oct$12.06
21 Oct$12.10
22 Oct$12.17
23 Oct$11.87
26 Oct$12.11
27 Oct$12.49
28 Oct$12.28
29 Oct$12.26
30 Oct$12.15
2 Nov$12.53
3 Nov$12.59
4 Nov$13.15
5 Nov$12.73
6 Nov$12.81
9 Nov$13.37
10 Nov$13.03
11 Nov$13.13
12 Nov$12.86
13 Nov$12.97
16 Nov$12.54

Industry Landscape

The personal services industry is navigating a period of rapid transformation, driven by the emergence of medical weight-loss solutions such as GLP-1 medications. Traditional wellness companies are adapting to a market where clinical interventions are gaining market share from behavioral and meal-replacement models. Within the consumer cyclical sector, firms are facing heightened customer acquisition costs as digital marketing efficiency fluctuates. Compared to peers in the health and wellness space, Medifast’s pivot toward integrated health coaching is a strategic attempt to differentiate its services from purely pharmaceutical approaches, though current revenue trends reflect the immediate impact of these broader industry headwinds.

Recent quarters and guidance
DateAnnouncementAmount
03 Aug 2026Q2 2026 revenue and guidanceSource: ir.medifastinc.com$76.4 Million
04 May 2026Q1 2026 revenue and guidanceSource: ir.medifastinc.com$76.0 Million
17 Feb 2026Q4 2025 revenue and guidanceSource: ir.medifastinc.com$75.1 Million
03 Nov 2025Q3 2025 revenue and guidanceSource: s204.q4cdn.com$89.4 Million
04 Aug 2025Q2 2025 revenue and guidanceSource: ir.medifastinc.com$105.6 Million
MEDIFAST INC · financial snapshot
Share price$11.87
Market cap$133M
Revenue (annual)$386M
1-month price change-0.67%
SectorConsumer CyclicalPersonal Services

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Medifast Inc announcing its financial results for the third quarter ended September 30, 2026.

Read the filing ↗

Track MEDIFAST INC live

Get the next MEDIFAST INC SEC filing seconds after it lands.

More in Results & Earnings

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.